Pacira BioSciences (PCRX) vs Tilray Brands (TLRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Tilray Brands (TLRY) over the past year, gaining 57.5% versus a loss of 79.1%. Over five years, PCRX leads with a -31.7% price change compared with -96.5% for TLRY. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $523.1 million), about 2.8 times the size.
On valuation, Tilray Brands trades at a lower forward P/E (8.0x vs 10.5x for Pacira BioSciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCRX | TLRY |
|---|---|---|
| Share price | $36.31 | $3.54 |
| Market cap | $1.45B | $523.15M |
| 1-day change | -0.22% | -1.39% |
| YTD return | +40.30% | -60.24% |
| 1-year return | +57.46% | -79.13% |
| 5-year return | -31.75% | -96.49% |
| P/E ratio (TTM) | 103.74 | — |
| Forward P/E | 10.50 | 8.05 |
| EPS (TTM) | $0.35 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $726.41M | — |
| Revenue growth (YoY) | +3.63% | — |
| Net income (latest FY) | $7.03M | — |
| Gross margin | 79.39% | — |
| Operating margin | 2.64% | — |
| Net margin | 0.97% | — |
| 52-week high | $36.46 | $20.20 |
| 52-week low | $18.80 | $3.38 |
| Distance from 52-week high | -0.41% | -82.48% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -17.08% | +102.26% |
| Average volume | 1.03M | 4.17M |
| Shares outstanding | 39.91M | 147.78M |
| Employees | 825 | 3,595 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pacira BioSciences is about 2.8 times larger than Tilray Brands by market value ($1.45B vs $523.15M).
- PCRX has outperformed TLRY by 136.6 percentage points over the past year.
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
About Tilray Brands
TLRY stock →Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness.
Health Care · Medicinal Chemicals and Botanical Products · 3,595 employees
PCRX vs TLRY FAQ
Which is bigger, Pacira BioSciences or Tilray Brands?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $523.15M for Tilray Brands (TLRY).
Which stock has performed better over the past year, PCRX or TLRY?
PCRX returned +57.46% over the past 12 months, compared with -79.13% for TLRY (price return, excluding dividends). Past performance does not predict future results.
Are Pacira BioSciences and Tilray Brands in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Pacira BioSciences and Medicinal Chemicals and Botanical Products for Tilray Brands.